Martin David Harp

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for dry eye disease.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Perimeter Medical Imaging AI has been leveraging the technology to improve breast cancer surgeries and reduce the number of patients requiring repeat surgery.

A PDUFA decision date of April 2, 2025 has been assigned

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in Chicago, Illinois, he stopped by the Eye Care Network booth to share insights from the symposium "Professional Longevity 2.0: Assessing the Ophthalmologist," which he presented during.

Christine Kay, MD sat down to discuss her presentation on gildeuretinol and its slowing of progression of Stargardt disease, studied in the TEASE program at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Christina Y Weng, MD, MBA sat down to discuss the Retina Ophthalmic Technology Assessment Symposium and her journal on teleretinal screening for diabetic eye disease at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The Eye Care Network adds a longstanding, CME-certified to its live event programming.

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.